U.S. patent number 3,874,380 [Application Number 05/473,372] was granted by the patent office on 1975-04-01 for dual nozzle intranasal delivery device.
This patent grant is currently assigned to SmithKline Corporation. Invention is credited to Ronald Baum.
United States Patent |
3,874,380 |
Baum |
April 1, 1975 |
DUAL NOZZLE INTRANASAL DELIVERY DEVICE
Abstract
A dual nozzle intranasal delivery device has a housing having a
cavity for the reception of a container, an opening for the
reception of a syringe nozzle, and a passage connecting said cavity
and said opening. A hollow needle is secured in the passage and
extends into the cavity, said needle being adapted to penetrate the
stopper of the container. A pair of adjacent spray nozzles having
substantially parallel axes are in communication with a conduit in
the housing which has an opening for the reception of a syringe
nozzle.
Inventors: |
Baum; Ronald (Merion Station,
PA) |
Assignee: |
SmithKline Corporation
(Philadelphia, PA)
|
Family
ID: |
23879260 |
Appl.
No.: |
05/473,372 |
Filed: |
May 28, 1974 |
Current U.S.
Class: |
128/200.14;
128/203.22; 141/27; 141/383; 604/414; 604/94.01; 128/203.21;
141/329; 604/201 |
Current CPC
Class: |
A61M
11/007 (20140204); A61M 15/08 (20130101); A61M
15/0028 (20130101); A61M 15/0036 (20140204); A61M
2205/073 (20130101); A61M 2202/0468 (20130101); A61M
16/0666 (20130101) |
Current International
Class: |
A61M
15/08 (20060101); A61M 15/00 (20060101); A61m
003/00 () |
Field of
Search: |
;128/206,207,208,215,218,235,247,272,173H ;141/383,329,27,2 |
References Cited
[Referenced By]
U.S. Patent Documents
Primary Examiner: Gaudet; Richard A.
Assistant Examiner: Recla; Henry J.
Attorney, Agent or Firm: Smith, Harding, Earley &
Follmer
Claims
I claim:
1. A dual nozzle intranasal delivery device comprising:
a housing,
said housing having a cavity for the reception of a container
having a pierceable stopper,
an opening for the reception of a syringe nozzle and a passage
connecting said cavity and said opening,
a hollow needle secured in said passage by a pressed fit and
extending into the cavity, said needle being adapted to penetrate
the stopper of said container,
a pair of adjacent nozzles having substantially parallel axes,
said housing having a conduit communicating with said nozzles and
having a second opening for the reception of a syringe nozzle, and
a second passage connecting said second opening with said
nozzles,
whereby liquid can be introduced into and withdrawn from a
container and then discharged through the nozzles.
Description
BACKGROUND OF THE INVENTION
It is known to employ a pair of adjacent spray nozzles
communicating with a conduit which is adapted to be connected to a
syringe to deliver vaccine such as a flu vaccine or a measles
vaccine in about equal doses to each nostril. While this operation
is simple and effective, it still leaves the patient with a
difficult problem in getting the dosage in liquid form in the
syringe. This is particularly the case where the biological to be
employed is lyophilized. In accordance with this invention a
lyophilized medicament can be placed in solution in a syringe under
sterile conditions with great ease by an unskilled patient.
BRIEF SUMMARY OF THE INVENTION
A dual nozzle intranasal delivery device has a housing having a
cavity for the reception of a container, an opening for the
reception of a syringe nozzle, and a passage connecting said cavity
and said opening. A hollow needle is secured in the passage and
extends into the cavity, said needle being adapted to penetrate the
stopper of the container. A pair of adjacent spray nozzles having
substantially parallel axes are in communication with a conduit in
the housing which has an opening for the reception of a syringe
nozzle.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an exploded view of an intranasal delivery device in
accordance with the invention together with a container and a
syringe;
FIG. 2 is a section through the intranasal device of FIG. 1;
FIG. 3 is a view of the intranasal device of FIG. 1 taken on the
plane indicated by the line 3--3 in FIG. 2; and
FIG. 4 is an elevational view of the intranasal device of FIG. 1
shown together with a syringe.
DETAILED DESCRIPTION
An intranasal device 2 has a housing 4 provided with a cylindrical
cavity 6 adapted to receive a container 8 typically containing a
tablet 10 of a lyophilized biological. Container 10 is of a type
well known to the art and has a pierceable rubber stopper 14 which
is held in position by a metal cap 16. Any of the wide variety of
containers currently employed with syringes provided with a needle
for piercing a container stopper may be employed.
Housing 4 has a passage 18 in which a hollow needle 20 is secured
by a pressed fit. Needle 20 extends into cavity 6 and has a sharp
chamfered outer end 22. Passage 18 communicates with a tapered
opening 26 which is adapted to receive tapered nozzle 28 of a
syringe 30. A stopper 32 is provided to close off nozzle 28. A
plunger 34 is provided for the discharge of liquid through nozzle
28 and for the intake of liquid through the nozzle. Syringe 30 is
well known to the art.
Housing 4 has a tapered opening 40 adapted to receive a syringe
nozzle such as the nozzle 28. Opening 40 is in communication with a
conduit 44 which has a pair of branches 46 and 48. A pair of spray
nozzles 52 and 54 are substantially parallel and spaced apart a
distance to permit one spray nozzle to enter each nostril. Each of
the spray nozzles has a cap 56 having a discharge passage 58, the
passages 58, 58 being substantially parallel. Each cap 56 has an
interior opening 60 which is adapted to receive branches 46 and 48
respectively and a bead 62 adapted to snap into grooves 64 and 66
respectively in branches 46 and 48. Branch 46 has a side opening 70
which discharges into cavity 72 in the cap 56 mounted on branch 46.
Similarly branch 48 has a side discharge opening 74 which
discharges into cavity 76 of the cap 56 mounted on branch 48. The
spray nozzles per se are conventional and any spray nozzles
conventionally used for spraying liquids into the nose may be
employed.
OPERATION
Assuming that a lyophilized biological such as the tablet 10 is to
be administered, container 8 is inserted into cavity 6 and thrust
home causing needle 20 to pierce the pierceable rubber stopper 14
and extend into the interior of container 8. With nozzle 28
pointing upwardly, cover 32 is removed from nozzle 28 of syringe 30
which contains a suitable reconstituting liquid and the nozzle 28
is inserted into opening 26. Plunger 34 is then advanced to force
the reconstituting liquid from syringe 30 into container 8. When
the biological tablet 10 has dissolved in the reconstituting
liquid, plunger 34 is retracted to draw the thus formed solution
into the syringe 30. The syringe 30 is now withdrawn from opening
26 and its nozzle is inserted into opening 40. With the spray
nozzles 52 and 54 inserted into the patient's nostrils, plunger 34
is depressed so as to force the contained liquid into conduit 44
and equally through branches 46 and 48 and through spray nozzles 52
and 54.
It will be understood that the foregoing description is
illustrative and not limiting.
* * * * *